This test builds on the Generalized Anxiety Disorder 7-item scale (GAD-7), published in 2006 by Spitzer, Kroenke, Williams and Löwe in Archives of Internal Medicine. Each of its 7 items maps to DSM-5-TR markers for generalized anxiety disorder (APA, 2022), anchored to a 2-week recall window. The instrument is © Pfizer Inc. and free for clinical, research, and educational use under Pfizer's free-use license — no permission required, attribution mandatory.
The DSM-5-TR defines generalized anxiety disorder as excessive worry, more days than not for at least 6 months, that the person finds difficult to control, paired with three or more associated symptoms (restlessness, fatigue, concentration trouble, irritability, muscle tension, sleep disturbance) and clinically significant impairment in social, occupational, or other important areas of functioning. Beyond the GAD-7, you answer a short context chapter (age, current situation, symptom duration) and a differential chapter that explores other possible leads — depression, panic, social anxiety, post-traumatic stress — so the report can flag what may look like generalized anxiety without being it.
Spitzer et al. (2006) reported a sensitivity of 89% and a specificity of 82% for generalized anxiety disorder at the ≥ 10 cutoff against a structured interview with a mental health professional (N = 2 740 primary-care patients). Plummer et al. (2016, General Hospital Psychiatry, meta-analysis of 12 studies) reported pooled sensitivity around 83% and specificity around 84% at the same cutoff across diverse populations — consistent across primary-care, hospital, and community samples. The GAD-7 is the screening instrument recommended by primary-care bodies worldwide and used by clinicians to monitor treatment response between visits.
A few numbers for context: per the NIMH generalized anxiety disorder page (2024), GAD affects a meaningful share of US adults each year, and the NHS (2024) reports that generalized anxiety disorder is among the most common anxiety disorders in UK adults. Across population studies, women are about twice as likely as men to develop generalized anxiety disorder — a stable signal across countries. The WHO (2024) underlines that anxiety disorders are the most common mental-disorder category worldwide. On the treatment side, cognitive behavioural therapy (CBT) is the first-line treatment for generalized anxiety disorder per NIMH and NHS guidance; SSRIs and SNRIs are also used in first-line pharmacotherapy. Benzodiazepines (GABAergic anxiolytics) are not recommended for long-term GAD management — short, time-limited use only, given dependence risk. Early treatment markedly improves outcomes — best discussed with a health professional.